Metabolic associated liver disease

被引:1
|
作者
Testino, Gianni [1 ,3 ]
Pellicano, Rinaldo [2 ]
机构
[1] Polyclin San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O, Genoa, Italy
[2] Molinette SGAS Hosp, Unit Gastroenterol, Turin, Italy
[3] Polyclin San martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O Padigl 10,Piazzale R Benzi 10, I-16132 Genoa, Italy
关键词
Alcohol drinking; Metabolic syndrome; Non-alcoholic fatty liver disease; Diabetes mellitus; type; 2; NONALCOHOLIC FATTY LIVER; ALCOHOL-USE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BLOOD-PRESSURE; FIBROSIS; RISK; IDENTIFICATION; PERFORMANCE; MANAGEMENT;
D O I
10.23736/S0031-0808.22.04730-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In real practice the patient with liver disease is often the carrier of multiple etiological factors such as metabolic syndrome (MS) and alcohol consumption (AC). Their copresence is often underestimated and AC is not adequately studied. Traditionally to diagnose non-alcoholic fatty liver disease (NAFLD), AC must not exceed 30 gr for men and 20 gr for women per day. This limit should still be reduced, especially in relation to the AC and fibrogenesis ratio and also frequent misestimation of AC or unrecognized MS may underestimate multi caused liver injury. AC is a contributing cause of MS and alcoholic and non-alcoholic liver disease have a substantially overlapping histopathological picture. Moreover, AC and MS are cause and contributing cause of extra-hepatic morbidity and mortality. It can be concluded that the possible simplification of terminology at metabolic associated liver disease (MALD) makes clinical activity more usable and immediate, facilitates better communication and cooperation between scientific societies and specialists who apparently deal with different medical sectors, facilitates early identification of related hepatic and extra-hepatic pathology, allows to "see the person in a unitary way," to create more streamlined care pathways, to reduce the hospitalization rate with relative cost-benefit advantage and to create unitary prevention and health promotion policies.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [31] Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Llamoza-Torres, Camilo Julio
    Fuentes-Pardo, Maria
    Ramos-Molina, Bruno
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [32] Cardiovascular disease in metabolic-associated fatty liver disease
    Adams, Leon A.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2023, 30 (02) : 81 - 86
  • [33] Endocrinologist's crucial role in metabolic dysfunction-associated steatotic liver disease: a comprehensive review
    Reytor-Gonzalez, Claudia
    Annunziata, Giuseppe
    Campuzano-Donoso, Martin
    Morales-Lopez, Tania
    Basantes-Tituana, Carmen
    Fasci-Spurio, Federica
    Verde, Ludovica
    Muscogiuri, Giovanna
    Barrea, Luigi
    Frias-Toral, Evelyn
    Simancas-Racines, Daniel
    MINERVA ENDOCRINOLOGY, 2025,
  • [34] Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
    Cheng, Yu-Ming
    Hsieh, Tsung-Han
    Wang, Shan-Wen
    Wang, Chia-Chi
    Kao, Jia-Horng
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 10 (04) : 249 - 256
  • [35] Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy
    Park, Huiyul
    Yoon, Eileen L.
    Kim, Mimi
    Cho, Seon
    Nah, Eun-Hee
    Jun, Dae Won
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (04) : 1041 - +
  • [36] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025, : 94 - 103
  • [37] Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Song, Byeong Geun
    Choi, Sung Chul
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Seung Woon
    JHEP REPORTS, 2023, 5 (09)
  • [38] Pregnancy and Metabolic- Associated Fatty Liver Disease
    Mandato, Claudia
    Panera, Nadia
    Alisi, Anna
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 521 - 531
  • [39] NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature?
    Gastaldelli, Amalia
    Newsome, Philip N.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [40] Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist
    Yeh, Ming-Lun
    Huang, Jee-Fu
    Dai, Chia-Yen
    Huang, Chung-Feng
    Yu, Ming-Lung
    Chuang, Wan-Long
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (08) : 431 - 439